JP2021500375A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021500375A5 JP2021500375A5 JP2020523244A JP2020523244A JP2021500375A5 JP 2021500375 A5 JP2021500375 A5 JP 2021500375A5 JP 2020523244 A JP2020523244 A JP 2020523244A JP 2020523244 A JP2020523244 A JP 2020523244A JP 2021500375 A5 JP2021500375 A5 JP 2021500375A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- amino acid
- acid sequence
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CCC(C)C(C(NCC(NC(C*C(*1)=C(C(C2)C2C(NC2)=O)c3c1c(C)c(*)c(*)c3*C)C(NC(CC(*)=O)C(N(CC(C)C1)C1C([C@](C)NC(C(C)C(*)C*)C(N)=O)=O)=O)=O)=O)=O)NC2=O Chemical compound CCC(C)C(C(NCC(NC(C*C(*1)=C(C(C2)C2C(NC2)=O)c3c1c(C)c(*)c(*)c3*C)C(NC(CC(*)=O)C(N(CC(C)C1)C1C([C@](C)NC(C(C)C(*)C*)C(N)=O)=O)=O)=O)=O)=O)NC2=O 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023078719A JP7641452B2 (ja) | 2017-10-24 | 2023-05-11 | Ｃｄ１１７＋細胞を減少させるための組成物及び方法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762576572P | 2017-10-24 | 2017-10-24 | |
| US62/576,572 | 2017-10-24 | ||
| US201762596569P | 2017-12-08 | 2017-12-08 | |
| US62/596,569 | 2017-12-08 | ||
| US201862632967P | 2018-02-20 | 2018-02-20 | |
| US62/632,967 | 2018-02-20 | ||
| US201862638053P | 2018-03-02 | 2018-03-02 | |
| US62/638,053 | 2018-03-02 | ||
| PCT/US2018/057180 WO2019084064A2 (en) | 2017-10-24 | 2018-10-23 | COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023078719A Division JP7641452B2 (ja) | 2017-10-24 | 2023-05-11 | Ｃｄ１１７＋細胞を減少させるための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021500375A JP2021500375A (ja) | 2021-01-07 |
| JP2021500375A5 true JP2021500375A5 (OSRAM) | 2021-12-09 |
| JP7280254B2 JP7280254B2 (ja) | 2023-05-23 |
Family
ID=66247007
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020523244A Active JP7280254B2 (ja) | 2017-10-24 | 2018-10-23 | Ｃｄ１１７＋細胞を減少させるための組成物及び方法 |
| JP2023078719A Active JP7641452B2 (ja) | 2017-10-24 | 2023-05-11 | Ｃｄ１１７＋細胞を減少させるための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023078719A Active JP7641452B2 (ja) | 2017-10-24 | 2023-05-11 | Ｃｄ１１７＋細胞を減少させるための組成物及び方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10899843B2 (OSRAM) |
| EP (1) | EP3700568A4 (OSRAM) |
| JP (2) | JP7280254B2 (OSRAM) |
| KR (1) | KR20200069364A (OSRAM) |
| CN (1) | CN111372608B (OSRAM) |
| AU (1) | AU2018355244B2 (OSRAM) |
| BR (1) | BR112020008228A2 (OSRAM) |
| CA (1) | CA3079897A1 (OSRAM) |
| CO (1) | CO2020004906A2 (OSRAM) |
| IL (1) | IL274154A (OSRAM) |
| MX (1) | MX2020004140A (OSRAM) |
| SG (1) | SG11202003280SA (OSRAM) |
| WO (1) | WO2019084064A2 (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12485186B2 (en) | 2017-03-31 | 2025-12-02 | The Children's Medical Center Corporation | Antibody-mediated conditioning with immunosuppression to enable allogeneic transplantation |
| US10882915B2 (en) | 2017-10-24 | 2021-01-05 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of CD117+ cells |
| EP3700568A4 (en) | 2017-10-24 | 2021-11-10 | Magenta Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS |
| CN119857155A (zh) | 2017-11-29 | 2025-04-22 | 海德堡医药研究有限责任公司 | 用于耗尽cd5+细胞的组合物和方法 |
| AU2019265019B2 (en) | 2018-05-11 | 2025-11-06 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| US20200376135A1 (en) * | 2018-10-23 | 2020-12-03 | Magenta Therapeutics, Inc. | Fc silenced antibody drug conjugates (adcs) and uses thereof |
| EP3959242A4 (en) * | 2019-04-24 | 2023-09-13 | Magenta Therapeutics, Inc. | ANTRACYCLINE ANTIBODY-DRUG CONJUGATES AND THEIR USES |
| JP2022529726A (ja) * | 2019-04-24 | 2022-06-23 | マジェンタ セラピューティクス インコーポレイテッド | Ａｎｔｉ－ｃｄ１１７とその使用 |
| MX2021012961A (es) * | 2019-04-24 | 2021-11-25 | Heidelberg Pharma Res Gmbh | Conjugados de anticuerpo y farmaco de amatoxina y usos de los mismos. |
| AU2020261079A1 (en) * | 2019-04-24 | 2021-12-23 | Regeneron Pharmaceuticals, Inc. | Conditioning methods for gene therapy |
| EP3958899A4 (en) * | 2019-04-24 | 2023-08-02 | Magenta Therapeutics, Inc. | ANTI-CD117 ANTIBODY-DRUG CONJUGATES AND THEIR USES |
| SG11202113331QA (en) | 2019-06-04 | 2021-12-30 | Magenta Therapeutics Inc | Methods and compositions for treating autoimmune diseases |
| WO2020247872A1 (en) * | 2019-06-05 | 2020-12-10 | Magenta Therapeutics, Inc. | T-cell depleting therapies |
| AU2021239929A1 (en) * | 2020-03-16 | 2022-10-13 | Crispr Therapeutics Ag | T-cell bispecific binding proteins |
| WO2023002415A2 (en) * | 2021-07-20 | 2023-01-26 | Magenta Therapeutics, Inc. | Methods and compositions for anti-cd117 antibody drug conjugate (adc) treatment |
| AU2022409748A1 (en) | 2021-12-16 | 2024-05-23 | Cimeio Therapeutics Ag | Discernible cell surface protein variants of cd117 for use in cell therapy |
| KR20250034296A (ko) | 2022-07-07 | 2025-03-11 | 씨메이오 테라퓨틱스 아게 | Cd117을 표적화하는 항체 |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| WO2024121632A1 (en) | 2022-12-09 | 2024-06-13 | Crispr Therapeutics Ag | Use of anti-cd117 antibody drug conjugate (adc) |
| WO2025235862A1 (en) | 2024-05-10 | 2025-11-13 | Inndura Therapeutics Inc. | A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19600589C1 (de) * | 1996-01-10 | 1997-01-16 | Univ Eberhard Karls | Antikörper A3C6E2 |
| US6093795A (en) | 1996-12-13 | 2000-07-25 | Human Genome Sciences, Inc. | Isolated human Prt1 protein |
| US6372448B1 (en) | 1998-12-30 | 2002-04-16 | Millennium Pharmaceuticals, Inc. | Use of ylqF, yqeG, yybQ, and ysxC, essential bacterial genes and polypeptides |
| US20040067532A1 (en) | 2002-08-12 | 2004-04-08 | Genetastix Corporation | High throughput generation and affinity maturation of humanized antibody |
| JP2008515774A (ja) | 2004-08-03 | 2008-05-15 | ダイアックス コーポレイション | ｈＫ１結合タンパク質 |
| ES2402576T3 (es) | 2005-11-14 | 2013-05-06 | Bioren, Inc. | Ultrahumanización de anticuerpos por generación y selección de bibliotecas cohorte y blast de cdr maduras previstas |
| TWI395754B (zh) * | 2006-04-24 | 2013-05-11 | Amgen Inc | 人類化之ｃ-ｋｉｔ抗體 |
| ATE521366T1 (de) | 2006-05-27 | 2011-09-15 | Faulstich Heinz Dr | Anwendung von amatoxin-konjugaten und phallotoxin-konjugaten mit makromolekülen zur krebstherapie und therapie von entzündungen |
| PT3255061T (pt) | 2006-11-03 | 2021-07-26 | Univ Leland Stanford Junior | Imunodepleção seletiva de nicho de células estaminais endógenas para enxerto |
| WO2009013543A2 (en) | 2007-07-25 | 2009-01-29 | Astrazeneca Ab | Targeted binging agents directed to kdr and uses thereof - 035 |
| JO3096B1 (ar) | 2008-11-07 | 2017-03-15 | Imclone Llc | الأجسام المضادة لمستقبل ii مضاد tgfb |
| PL3290052T3 (pl) | 2008-11-07 | 2020-06-29 | Galaxy Biotech, Llc | Przeciwciała monoklonalne swoiste dla receptora 2 czynnika wzrostu fibroblastów |
| US9233173B2 (en) | 2009-04-08 | 2016-01-12 | Deutsches Krebsforschungszentrum | Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy |
| US20130022603A1 (en) | 2010-02-18 | 2013-01-24 | Symphogen A/S | Antibody against serotype i lipopolysaccharide of pseudomonas aeruginosa |
| KR101653030B1 (ko) | 2010-08-13 | 2016-08-31 | 로슈 글리카트 아게 | 항-테나신-c a２ 항체 및 이의 사용 방법 |
| EP2436398B1 (en) | 2010-09-30 | 2013-01-23 | Heidelberg Pharma GmbH | Amatoxin-conjugates with improved linkers |
| WO2012103163A2 (en) * | 2011-01-25 | 2012-08-02 | The Cleveland Clinic Foundation | Compositions and methods for treating cancer while preventing or reducing cardiotoxicity and/or cardiomyopathy |
| EP3763740A1 (en) * | 2011-01-26 | 2021-01-13 | Celldex Therapeutics, Inc. | Anti-kit antibodies and uses thereof |
| EP2497499A1 (en) | 2011-03-10 | 2012-09-12 | Heidelberg Pharma GmbH | Amatoxin-conjugates with improved linkages |
| AR086044A1 (es) * | 2011-05-12 | 2013-11-13 | Imclone Llc | Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos |
| EP2774624A1 (en) | 2013-03-04 | 2014-09-10 | Heidelberg Pharma GmbH | Amatoxin derivatives |
| FR3008408B1 (fr) | 2013-07-11 | 2018-03-09 | Mc Saf | Nouveaux conjugues anticorps-medicament et leur utilisation en therapie |
| US20160177390A1 (en) | 2013-07-12 | 2016-06-23 | Biogen International Neuroscience Gmbh | Genetic and image biomarkets associated with decline in cognitive measures and brain glucose metabolism in populations with alzheimer's disease or those susceptible to developing alzheimer's disease |
| WO2015057942A1 (en) | 2013-10-18 | 2015-04-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies against the middle east respiratory syndrome coronavirus (mers-cov) and engineered bispecific fusions with inhibitory peptides |
| WO2015067667A1 (en) * | 2013-11-05 | 2015-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Human neutralizing anti-kit antibodies and uses thereof |
| WO2015138600A2 (en) | 2014-03-11 | 2015-09-17 | The Board Of Trustees Of The Leland Stanford Junior University | Anti sirp-alpha antibodies and bi-specific macrophage enhancing antibodies |
| WO2016020791A1 (en) * | 2014-08-05 | 2016-02-11 | Novartis Ag | Ckit antibody drug conjugates |
| US9938323B2 (en) | 2014-11-06 | 2018-04-10 | Novartis Ag | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase |
| DK3268047T3 (da) | 2015-03-09 | 2024-01-02 | Heidelberg Pharma Res Gmbh | Amatoxin/antistof-konjugater |
| WO2016154588A1 (en) | 2015-03-25 | 2016-09-29 | Children's Hospital Medical Center | Use of kit inhibitors to condition subjects for a hematopoietic stem cell (hsc) transplantation |
| WO2016164502A1 (en) | 2015-04-06 | 2016-10-13 | President And Fellows Of Harvard College | Compositions and methods for non-myeloablative conditioning |
| EP3991748A3 (en) | 2015-04-07 | 2022-08-24 | Alector LLC | Anti-sortilin antibodies and methods of use thereof |
| WO2016164745A1 (en) * | 2015-04-10 | 2016-10-13 | The Methodist Hospital System | Cd117 ligand-drug conjugates for targeted cancer therapy |
| BR112018002570A2 (pt) | 2015-10-02 | 2018-10-16 | Hoffmann La Roche | molécula de ligação ao antígeno biespecífica, anticorpo biespecífico, polinucleotídeos, anticorpo que se liga especificamente ao ox40, composição farmacêutica e método para inibir o crescimento de células tumorais em um indivíduo |
| KR20250099459A (ko) | 2015-11-03 | 2025-07-01 | 얀센 바이오테크 인코포레이티드 | Pd-1과 특이적으로 결합하는 항체 및 그의 용도 |
| JP7676100B2 (ja) | 2016-02-05 | 2025-05-14 | ジェンマブ アクティーゼルスカブ | 改善された内部移行特性を有する多重特異性抗原結合分子 |
| MX2018012803A (es) | 2016-04-20 | 2019-06-24 | Hangzhou Dac Biotech Co Ltd | Derivados de las toxinas de amanita y su conjugacion a una molecula de union celular. |
| US10464969B2 (en) | 2016-05-05 | 2019-11-05 | Novartis Ag | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase |
| MX2018015684A (es) | 2016-06-17 | 2019-08-29 | Magenta Therapeutics Inc | Composiciones y metodos para el agotamiento de celulas cd117. |
| US12485186B2 (en) | 2017-03-31 | 2025-12-02 | The Children's Medical Center Corporation | Antibody-mediated conditioning with immunosuppression to enable allogeneic transplantation |
| EP3700568A4 (en) | 2017-10-24 | 2021-11-10 | Magenta Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS |
| US10882915B2 (en) | 2017-10-24 | 2021-01-05 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of CD117+ cells |
-
2018
- 2018-10-23 EP EP18870545.3A patent/EP3700568A4/en active Pending
- 2018-10-23 WO PCT/US2018/057180 patent/WO2019084064A2/en not_active Ceased
- 2018-10-23 MX MX2020004140A patent/MX2020004140A/es unknown
- 2018-10-23 AU AU2018355244A patent/AU2018355244B2/en not_active Expired - Fee Related
- 2018-10-23 BR BR112020008228-7A patent/BR112020008228A2/pt not_active Application Discontinuation
- 2018-10-23 US US16/168,823 patent/US10899843B2/en active Active
- 2018-10-23 CN CN201880075607.2A patent/CN111372608B/zh active Active
- 2018-10-23 SG SG11202003280SA patent/SG11202003280SA/en unknown
- 2018-10-23 JP JP2020523244A patent/JP7280254B2/ja active Active
- 2018-10-23 CA CA3079897A patent/CA3079897A1/en active Pending
- 2018-10-23 KR KR1020207014624A patent/KR20200069364A/ko active Pending
-
2020
- 2020-04-21 CO CONC2020/0004906A patent/CO2020004906A2/es unknown
- 2020-04-22 IL IL274154A patent/IL274154A/en unknown
- 2020-11-24 US US17/103,866 patent/US11958908B2/en active Active
-
2023
- 2023-05-11 JP JP2023078719A patent/JP7641452B2/ja active Active
-
2024
- 2024-04-04 US US18/626,765 patent/US20240360238A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7641452B2 (ja) | Ｃｄ１１７＋細胞を減少させるための組成物及び方法 | |
| US11572411B2 (en) | Anti-CD117 antibodies and conjugates | |
| JP7791923B2 (ja) | Ｃｄ５＋細胞の枯渇のための組成物および方法 | |
| JP7669269B2 (ja) | 抗－ｃｄ４５抗体及びそのコンジュゲート | |
| JP7709376B2 (ja) | Ｆｃサイレンス化抗体薬物コンジュゲート（ＡＤＣ）及びその使用 | |
| JP7716399B2 (ja) | 抗－ｃｄ４５抗体及びそのコンジュゲート | |
| JP2025038016A (ja) | 同種異系の造血幹細胞移植の方法 | |
| US20220177575A1 (en) | Anti-cd117 antibodies and uses thereof | |
| JP2022529726A5 (OSRAM) | ||
| JP2021504414A (ja) | Ｃｄ２＋細胞の枯渇のための組成物および方法 | |
| US20220177578A1 (en) | Anti-cd117 antibodies and uses thereof | |
| JP2022529727A5 (OSRAM) | ||
| EP3740233A2 (en) | Compositions and methods for the depletion of cd134+ cells |